Using clinical registries to improve outcomes for future patients | Dr Koen Degeling
Health and process outcomes captured in clinical registries provide valuable insights into real-world treatment patterns, but how can we use those data to evaluate current cancer treatments and inform treatment decisions for future patients?
Dr Koen Degeling
University of Melbourne Centre for Cancer Research (UMCCR) and School of Population and Global Health
22 April 2020
The value of clinical registries to provide insight into real-world treatment patterns has been acknowledged and demonstrated, but there is additional potential for such registries to inform health economic evaluations of cancer treatments and support future treatment decisions. Since clinical registries typically represent a real-world patient population, they can be used to address important concerns regarding the generalizability of health economic evaluations informed by clinical trial data.
This presentation demonstrates the use of the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry to evaluate the real-world health economic impact of adding bevacizumab to doublet chemotherapy for first-line treatment of RAS mutant metastatic colorectal cancer. Dr Degeling discusses how a personalized simulation model based on TRACC data may potentially improve patient outcomes through better-informed treatment decisions.
Dr Koen Degeling
Dr Koen Degeling is a Research Fellow within the Cancer Health Services Research group of the University of Melbourne Centre for Cancer Research and School of Population and Global Health. His research focuses on the application of operations research methods in healthcare to evaluate and optimize oncology pathways. Koen has a particular interest in the use of real-world data to populate health economic models.